Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents^1,2,3,4,5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses—particularly the B.1.617.1 variant—seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 正在世界范围内继续发展，产生新的变体，这些变体可能会改变传播性、致病性以及疫苗和治疗剂的覆盖率^{1,2 ,3,4,5}. 在这里，我们展示了在第二剂 BNT162b2 疫苗接种后两到四周从 20 名人类志愿者身上采集的血清样本，中和了具有 USA-WA1/2020 遗传背景的工程 SARS-CoV-2（一种于 2020 年 1 月分离的病毒株）和来自最近发现的 B.1.617.1、B.1.617.2、B.1.618（所有这些都是在印度首次发现）或 B.1.525（在尼日利亚首次发现）谱系中的刺突糖蛋白。针对变体病毒（尤其是 B.1.617.1 变体）的几何平均空斑减少中和滴度似乎低于针对 USA-WA1/2020 病毒的滴度，但所有测试的血清均以至少 1 的滴度中和变体病毒:40。